391 related articles for article (PubMed ID: 23903326)
41. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
[TBL] [Abstract][Full Text] [Related]
42. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Grzesk G; Kozinski M; Navarese EP; Krzyzanowski M; Grzesk E; Kubica A; Siller-Matula JM; Castriota F; Kubica J
Thromb Res; 2012 Jul; 130(1):65-9. PubMed ID: 22265722
[TBL] [Abstract][Full Text] [Related]
43. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Sugidachi A; Ogawa T; Kurihara A; Hagihara K; Jakubowski JA; Hashimoto M; Niitsu Y; Asai F
J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
[TBL] [Abstract][Full Text] [Related]
44. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
Lhermusier T; Lipinski MJ; Tantry US; Escarcega RO; Baker N; Bliden KP; Magalhaes MA; Ota H; Tian W; Pendyala L; Minha S; Chen F; Torguson R; Gurbel PA; Waksman R
Am J Cardiol; 2015 Mar; 115(6):716-23. PubMed ID: 25728845
[TBL] [Abstract][Full Text] [Related]
45. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
[TBL] [Abstract][Full Text] [Related]
46. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa SA; Jeske WP; Fareed J
Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
[TBL] [Abstract][Full Text] [Related]
47. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
48. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
Koessler J; Kobsar AL; Rajkovic MS; Schafer A; Flierl U; Pfoertsch S; Bauersachs J; Steigerwald U; Rechner AR; Walter U
Platelets; 2011; 22(1):20-7. PubMed ID: 20873965
[TBL] [Abstract][Full Text] [Related]
49. 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Glenn JR; Dovlatova N; White AE; Dhillon K; Heptinstall S; Fox SC
Thromb Haemost; 2014 Mar; 111(3):539-48. PubMed ID: 24258486
[TBL] [Abstract][Full Text] [Related]
50. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E
Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327
[TBL] [Abstract][Full Text] [Related]
51. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
[TBL] [Abstract][Full Text] [Related]
52. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
[TBL] [Abstract][Full Text] [Related]
53. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition.
Jakubowski JA; Bourguet N; Boulay-Moine D; Sugidachi A; Yamaguchi S; Barragan P; Zhou C; Moulard M
Thromb Haemost; 2012 Feb; 107(2):388-95. PubMed ID: 22186965
[TBL] [Abstract][Full Text] [Related]
54. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
[TBL] [Abstract][Full Text] [Related]
55. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
56. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
[TBL] [Abstract][Full Text] [Related]
57. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
[TBL] [Abstract][Full Text] [Related]
58. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
[TBL] [Abstract][Full Text] [Related]
59. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.
Laine M; Frère C; Toesca R; Berbis J; Barnay P; Pansieri M; Michelet P; Bessereau J; Camilleri E; Ronsin O; Helal O; Paganelli F; Dignat-George F; Bonello L
Thromb Haemost; 2014 Feb; 111(2):273-8. PubMed ID: 24154787
[TBL] [Abstract][Full Text] [Related]
60. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
